

# **Hepatitis C - Pipeline Review, H1 2020**

https://marketpublishers.com/r/H8A164870D8EN.html

Date: March 2020

Pages: 414

Price: US\$ 2,000.00 (Single User License)

ID: H8A164870D8EN

### **Abstracts**

Hepatitis C - Pipeline Review, H1 2020

#### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H1 2020, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued



projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 9, 15, 3, 35, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 13 and 17 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

#### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.







## **Contents**

### Introduction

Hepatitis C - Overview

Hepatitis C - Therapeutics Development

Hepatitis C - Therapeutics Assessment

Hepatitis C - Companies Involved in Therapeutics Development

Hepatitis C - Drug Profiles

Hepatitis C - Dormant Projects

Hepatitis C - Discontinued Products

Hepatitis C - Product Development Milestones

Appendix



### **List Of Tables**

### LIST OF TABLES

Number of Products under Development for Hepatitis C, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Hepatitis C - Pipeline by AB Pharma Ltd, H1 2020

Hepatitis C - Pipeline by AbbVie Inc, H1 2020

Hepatitis C - Pipeline by AIMM Therapeutics BV, H1 2020

Hepatitis C - Pipeline by Akshaya Bio Inc, H1 2020

Hepatitis C - Pipeline by Alla Chem LLC, H1 2020

Hepatitis C - Pipeline by Ascletis Pharma Inc, H1 2020

Hepatitis C - Pipeline by Atea Pharmaceuticals Inc, H1 2020

Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2020

Hepatitis C - Pipeline by Beta Pharma Inc, H1 2020

Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H1 2020

Hepatitis C - Pipeline by Biotron Ltd, H1 2020

Hepatitis C - Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Hepatitis C - Pipeline by Bolder Biotechnology Inc, H1 2020

Hepatitis C - Dormant Projects, H1 2020

Hepatitis C - Discontinued Products, H1 2020



## **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Hepatitis C, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

#### **COMPANIES MENTIONED**

AB Pharma Ltd

AbbVie Inc

**AIMM Therapeutics BV** 

Akshaya Bio Inc

Alla Chem LLC

Ascletis Pharma Inc.

Atea Pharmaceuticals Inc

Beijing Kawin Technology Share-Holding Co Ltd

Beta Pharma Inc

Biotest Pharmaceuticals Corp

Biotron Ltd

Boehringer Ingelheim International GmbH

Bolder Biotechnology Inc

Bristol-Myers Squibb Co

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Cocrystal Pharma Inc

Combioxin SA

**DEKK-TEC Inc** 

Dongguan HEC TaiGen Biopharmaceuticals Co Ltd

Ena Therapeutics Pty Ltd

**Ennaid Therapeutics LLC** 



F. Hoffmann-La Roche Ltd

FortuneRock (China) Ltd

Galactica Biotech Ltd

GeneCure LLC

Genoscience Pharma

Gilead Sciences Inc

GinkgoPharma Co Ltd

GlaxoSmithKline Plc

HEC Pharm Co Ltd

Hepion Pharmaceuticals Inc

ImmuneMed Inc

ImmunoBiology Ltd

Immunotope Inc

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

iQur Ltd

J2H Biotech

Medivir AB

Merck & Co Inc.

MetalloPharm LLC

Microbio Co Ltd

MultiCell Technologies Inc

Nanjing Sanhome Pharmaceutical Co Ltd

Nanogen Biopharmaceutical Co

**Novalex Therapeutics Inc** 

Ono Pharmaceutical Co Ltd

Palisades Therapeutics

PharmaEssentia Corp

Presidio Pharmaceuticals Inc

Profectus BioSciences Inc

Regulus Therapeutics Inc

Riboscience LLC

Rodos BioTarget GmbH

Savoy Pharmaceuticals Inc

Shanghai Newsummit Biopharma Co Ltd

Shanghai Tangrun Pharmaceuticals Co Ltd

Sino Biopharmaceutical Ltd

Sudershan Biotech Ltd

TaiGen Biotechnology Co Ltd



Tetranov International Inc

TGV Laboratories Inc

Therapure Biopharma Inc

THEVAX Genetics Vaccine USA Inc

Toray Industries Inc

Trek Therapeutics PBC

**UBI** Pharma Inc

Vanworld Pharmaceutical (Rugao) Company Ltd

Vertex Pharmaceuticals Inc

Virocovax

Zylacta Corp



### I would like to order

Product name: Hepatitis C - Pipeline Review, H1 2020

Product link: <a href="https://marketpublishers.com/r/H8A164870D8EN.html">https://marketpublishers.com/r/H8A164870D8EN.html</a>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/H8A164870D8EN.html">https://marketpublishers.com/r/H8A164870D8EN.html</a>